Why Eli Lilly and Company (LLY) Stock Rose 6.6% on Oct 29, 2026
What happened
Eli Lilly reported third-quarter revenue of $24.4 billion (+39% YoY), beating consensus of $22.58 billion, and adjusted EPS of $7.48, far exceeding the $5.68 consensus, driven by blockbuster demand for GLP-1 drugs Mounjaro and Zepbound (Barron's, Zacks). Management raised full-year guidance following the beat. Stock surged +6.43% to $1,371.11 on elevated volume (3.84x expected for this time of session).
Earnings call commentary on Mounjaro and Zepbound supply constraints, penetration trends, and pricing power; any updates to full-year revenue and EPS guidance ranges.
Other developments that session
Eli Lilly and Company (LLY) reported EPS of $7.48 vs. $5.68 consensus estimate, beating by 31.7%.
Eli Lilly and Company (LLY) filed a new 8-K on October 29, 2026. The audit did not disclose the specific content of the filing.
LLY reported Q3 EPS of $7.48, exceeding consensus estimate of $5.38 by 39%.
Frequently asked questions
Why did Eli Lilly and Company (LLY) stock rise on Oct 29, 2026?
Eli Lilly reported third-quarter revenue of $24.4 billion (+39% YoY), beating consensus of $22.58 billion, and adjusted EPS of $7.48, far exceeding the $5.68 consensus, driven by blockbuster demand for GLP-1 drugs Mounjaro and Zepbound (Barron's, Zacks). Management raised full-year guidance following the beat. Stock surged +6.43% to $1,371.11 on elevated volume (3.84x expected for this time of session).
How much did LLY stock rise on Oct 29, 2026?
LLY rose 6.6% during the Oct 29, 2026 trading session.